Polycythemia vera secondary prevention

Jump to: navigation, search

Polycythemia vera Microchapters

Home

Patient Information

Overview

Historical perspective

Classification

Pathophysiology

Causes

Differentiating Polycythemia vera from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural history, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Polycythemia vera secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Polycythemia vera secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Polycythemia vera secondary prevention

CDC on Polycythemia vera secondary prevention

Polycythemia vera secondary prevention in the news

Blogs on Polycythemia vera secondary prevention

Directions to Hospitals Treating Polycythemia vera

Risk calculators and risk factors for Polycythemia vera secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2] Shyam Patel [3] Synonyms and Keywords: Polycythemia rubra vera (PRV); Erythremia; Primary polycythemia; Osler-Vaquez disease; splenomegalic polycythemia

Overview

Secondary prevention strategy following polycythemia vera include low dose aspirin.

Secondary Prevention

Secondary prevention strategy following polycythemia vera include low-dose aspirin 81mg daily to decrease the risk of the following complications:[1]

References

  1. Maeda T, Wakasawa T, Shima Y, Tsuboi I, Aizawa S, Tamai I (2006). "Role of polyamines derived from arginine in differentiation and proliferation of human blood cells". Biol Pharm Bull. 29 (2): 234–9. PMID 16462024.

Linked-in.jpg